You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The guidance says private health plans can't use medical screening criteria to deny coverage for COVID-19 diagnostic tests for asymptomatic patients.
Azova's kit is for use with Fluidigm's Advanta Dx SARS-CoV-2 RT-PCR assay, an extraction-free, saliva-based COVID test that previously received EUA.
The company also said that it had received EUA from the US Food and Drug Administration for a non-prescription version of its COVID-19 sample collection kit.
Of the 32 companies in the index, 14 firms saw their stock prices increase, while 18 saw their share prices decline.
Bio-Techne's CEO said the coverage decision will expand access to its EPI test and enable additional men to better decide whether to proceed with a prostate biopsy.
Hologic said that the transaction further strengthens its molecular diagnostics business by expanding its international capabilities, among other benefits.
The firm said it is drawing up plans for its business in a post-pandemic world, planning the introduction of new testing panels and enhancing its respiratory panel.
During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.
Labs like Biodesix, ARUP, Quest, and Labcorp engaged different strategies to prevent loss of patient samples during recent extreme weather.
The firm, in its development work, has multiplexed up to 57 different analytes, obtaining quantitative results using one cartridge and one patient sample, its CEO said.